JOP20230122A1 - العلاج بخلايا car-t المستهدفة لـ bcma لعلاج الورم النخاعي المتعدد - Google Patents

العلاج بخلايا car-t المستهدفة لـ bcma لعلاج الورم النخاعي المتعدد

Info

Publication number
JOP20230122A1
JOP20230122A1 JOJO/P/2023/0122A JOP20230122A JOP20230122A1 JO P20230122 A1 JOP20230122 A1 JO P20230122A1 JO P20230122 A JOP20230122 A JO P20230122A JO P20230122 A1 JOP20230122 A1 JO P20230122A1
Authority
JO
Jordan
Prior art keywords
car
multiple myeloma
patient
treatment
cell therapy
Prior art date
Application number
JOJO/P/2023/0122A
Other languages
Arabic (ar)
English (en)
Inventor
Jordan Mark Schecter
Xiaohu Fan
Original Assignee
Janssen Biotech Inc
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Nanjing Legend Biotech Co Ltd filed Critical Janssen Biotech Inc
Publication of JOP20230122A1 publication Critical patent/JOP20230122A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JOJO/P/2023/0122A 2020-12-03 2023-05-30 العلاج بخلايا car-t المستهدفة لـ bcma لعلاج الورم النخاعي المتعدد JOP20230122A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/133598 WO2022116086A1 (en) 2020-12-03 2020-12-03 Bcma-targeted car-t cell therapy for multiple myeloma
PCT/CN2021/135295 WO2022117068A1 (en) 2020-12-03 2021-12-03 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (1)

Publication Number Publication Date
JOP20230122A1 true JOP20230122A1 (ar) 2023-05-30

Family

ID=79270135

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0122A JOP20230122A1 (ar) 2020-12-03 2023-05-30 العلاج بخلايا car-t المستهدفة لـ bcma لعلاج الورم النخاعي المتعدد

Country Status (15)

Country Link
US (2) US20220265710A1 (https=)
EP (1) EP4255450A1 (https=)
JP (1) JP2023551877A (https=)
KR (1) KR20230118556A (https=)
CN (1) CN116888147A (https=)
AR (1) AR124248A1 (https=)
AU (1) AU2021392708A1 (https=)
CA (1) CA3203603A1 (https=)
IL (1) IL303312A (https=)
JO (1) JOP20230122A1 (https=)
MA (1) MA71426A (https=)
MX (1) MX2023006371A (https=)
TW (1) TW202237637A (https=)
UY (1) UY39555A (https=)
WO (2) WO2022116086A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020378263A1 (en) 2019-11-05 2022-06-23 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
CN116096498A (zh) * 2020-05-04 2023-05-09 生物诊断有限公司 诊断设备
WO2024146398A1 (zh) * 2023-01-04 2024-07-11 北京艺妙神州医药科技有限公司 分离的抗体、包含该抗体的car及其用途
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
SG10202012157QA (en) * 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
EP4282877A3 (en) * 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
CN119529091A (zh) * 2018-06-19 2025-02-28 南京传奇生物科技有限公司 工程化的细胞及其用途
JP2021532742A (ja) * 2018-07-26 2021-12-02 ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. Ｎｅｆを含むｔ細胞及びその生成方法

Also Published As

Publication number Publication date
MA71426A (fr) 2025-04-30
WO2022117068A1 (en) 2022-06-09
MX2023006371A (es) 2023-07-31
US20220265710A1 (en) 2022-08-25
CN116888147A (zh) 2023-10-13
JP2023551877A (ja) 2023-12-13
UY39555A (es) 2022-06-30
KR20230118556A (ko) 2023-08-11
WO2022116086A1 (en) 2022-06-09
CA3203603A1 (en) 2022-06-09
EP4255450A1 (en) 2023-10-11
TW202237637A (zh) 2022-10-01
AU2021392708A1 (en) 2023-06-22
IL303312A (en) 2023-07-01
AR124248A1 (es) 2023-03-01
US20240000836A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JOP20230122A1 (ar) العلاج بخلايا car-t المستهدفة لـ bcma لعلاج الورم النخاعي المتعدد
JOP20240104A1 (ar) العلاج بالخلايا التائية لمستقبل المستضد الخيمري (car) المستهدِفة لمستضد نضج الخلايا البائية (bcma) للورم النقوي المتعدد
Hill et al. CAR-T–and a side order of IgG, to go?–Immunoglobulin replacement in patients receiving CAR-T cell therapy
Tanaka et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
CN106062000B (zh) 通过施用il-4r拮抗剂治疗皮肤感染的方法
US9717731B2 (en) TEC family kinase inhibitor adjuvant therapy
JP2025172841A5 (https=)
JP2019521156A5 (https=)
EP4151210A3 (en) Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
Khandelwal et al. The successful use of alemtuzumab for treatment of steroid‐refractory acute graft‐versus‐host disease in pediatric patients
US4378351A (en) Methods of treating bacterial, viral or parasitic diseases
Stackowicz et al. Conditional neutrophil depletion challenges their contribution to mouse models of anaphylaxis
IE20230360A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
US4452781A (en) Method of treating bacterial viral or parasitic diseases
Grosicki et al. GEN3014 (HexaBody®-CD38) in anti-CD38 Mab-naive patients with relapsed/refractory multiple myeloma: preliminary results from a dose-expansion cohort of a phase 1/2 trial
Hutten et al. Successful desensitization to isatuximab in a patient with refractory multiple myeloma and indolent systemic mastocytosis. Reply to: anaphylactic shock due to isatuximab and successful desensitization
US4378350A (en) Method of treating bacterial, viral or parasitic diseases
RU2391100C1 (ru) Способ лечения больных грибковыми заболеваниями ногтей
US20260014196A1 (en) Compositions of molecular hydrogen, oxyhydrogen and therapeutic uses thereof
CN114129722B (zh) 注射用人免疫球蛋白在制备预防或治疗辐照损伤的药物中的用途
Gupta et al. BIMZELX®(Bimekizumab-bkzx) Injection, for Subcutaneous Use
Inzinger et al. Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab
Mostafa Modern therapies in vitiligo management
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用